alpha 1 adrenoceptor Inhibitors
1 drugsAbout alpha 1 adrenoceptor
The alpha 1 adrenoceptor (α1-adrenergic receptor) mediates norepinephrine and epinephrine effects, leading to vasoconstriction and increased blood pressure. As a receptor protein, it is a key target in cardiovascular drug development.
Modulation of this receptor has proven clinically relevant. However, there is currently no genetic evidence directly linking variations in the gene encoding the alpha 1 adrenoceptor to specific diseases.
The alpha 1 adrenoceptor is targeted by one FDA-approved drug, CARDURA (doxazosin), a small molecule developed by Viatris. It was first approved in 1990 for cardiovascular indications.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Alcohol Use Disorder (AUD) with only 1 trials.
Top alpha 1 adrenoceptor Drugs
Viatris is the only company with an approved drug targeting the alpha 1 adrenoceptor.
The market is highly concentrated, indicating potential entry barriers or limited commercial opportunity.
alpha 1 adrenoceptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets alpha 1 adrenoceptor, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could offer a competitive advantage in this space.
alpha 1 adrenoceptor Clinical Trials 15 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 6 | 6 | 0 | 0 | 100% |
| Phase 2 | 6 | 4 | 0 | 1 | 100% |
| Phase 3 | 1 | 1 | 0 | 0 | 100% |
| Phase 4 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
alpha 1 adrenoceptor Drug Approval Timeline (1990 - 1990)
The first and only drug, CARDURA, was approved in 1990.
The lack of recent approvals suggests a saturated market or challenges in developing new alpha 1 adrenoceptor-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 17 clinical trials targeting alpha 1 adrenoceptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities